No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S.

The US Food and Drug Administration has approved the new drug Cobenfy, which is owned by pharmaceutical firm Bristol Myers ...

That's where the greatest level of excitement is from." Roughly 1 percent of Americans suffer from schizophrenia, which is one of the 15 leading causes of disability worldwide, the FDA reports.

Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This ...

The Bristol Myers Squibb medicine is said relieve symptoms without causing some of the harsh side effects of drugs already in use. Meanwhile, thousands of patients allege in a lawsuit that drugs used ...

Stock futures were modestly higher ahead of the release of the Federal Reserve's preferred measures of inflation, as major ...

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.

The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and ...

There's a newly approved drug for schizophrenia from Bristol Myers Squibb.

Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The ...

As of now, Bristol Myers Squibb has registered a Year-to-Date (YTD) stock performance of +1.48%. This figure starkly contrasts with the S&P 500’s impressive YTD performance of +20.45%. While BMY’s ...

Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...